SGLT2 inhibitors are a welcome addition to GN care, but the field is still grappling with the gap between molecular ...
TG Therapeutics Makes 2025 Deloitte Technology Fast 500™ List of America's Fastest-Growing Companies
NEW YORK, Nov. 19, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced it ranked number 27 on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing ...
Trial met primary endpoint of hemoglobin response and key secondary endpoints of change from baseline in hemoglobin concentration and indirect bilirubin Trial showed trend favoring mitapivat but did ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback